Institut MITOVASC, Département de Médecine d'Urgence, CHU d'Angers, Université d'Angers, Angers, France.
Service de Médecine d'Urgence, CHU de Poitiers, Poitiers, France.
Intern Emerg Med. 2018 Oct;13(7):1111-1119. doi: 10.1007/s11739-018-1803-4. Epub 2018 Mar 2.
In patients consulting in the Emergency Department for chest pain, a HEART score ≤ 3 has been shown to rule out an acute coronary syndrome (ACS) with a low risk of major adverse cardiac event (MACE) occurrence. A negative CARE rule (≤ 1) that stands for the first four elements of the HEART score may have similar rule-out reliability without troponin assay requirement. We aim to prospectively assess the performance of the CARE rule and of the HEART score to predict MACE in a chest pain population. Prospective two-center non-interventional study. Patients admitted to the ED for non-traumatic chest pain were included, and followed-up at 6 weeks. The main study endpoint was the 6-week rate of MACE (myocardial infarction, coronary angioplasty, coronary bypass, and sudden unexplained death). 641 patients were included, of whom 9.5% presented a MACE at 6 weeks. The CARE rule was negative for 31.2% of patients, and none presented a MACE during follow-up [0, 95% confidence interval: (0.0-1.9)]. The HEART score was ≤ 3 for 63.0% of patients, and none presented a MACE during follow-up [0% (0.0-0.9)]. With an incidence below 2% in the negative group, the CARE rule seemed able to safely rule out a MACE without any biological test for one-third of patients with chest pain and the HEART score for another third with a single troponin assay.
在因胸痛到急诊科就诊的患者中,HEART 评分 ≤ 3 已被证明可排除急性冠状动脉综合征(ACS),且发生主要不良心脏事件(MACE)的风险较低。排除 ACS 的 CARE 规则(≤ 1),代表 HEART 评分的前四项,可能具有类似的排除可靠性,而无需进行肌钙蛋白检测。我们旨在前瞻性评估 CARE 规则和 HEART 评分在胸痛人群中预测 MACE 的性能。前瞻性、双中心、非干预性研究。纳入因非创伤性胸痛而收入急诊科的患者,并在 6 周时进行随访。主要研究终点为 6 周时的 MACE 发生率(心肌梗死、经皮冠状动脉介入治疗、冠状动脉旁路移植术和突发性不明原因死亡)。共纳入 641 例患者,其中 9.5%在 6 周时发生 MACE。31.2%的患者 CARE 规则为阴性,且随访期间无患者发生 MACE [0,95%置信区间:(0.0-1.9)]。63.0%的患者 HEART 评分为 ≤ 3,且随访期间无患者发生 MACE [0%(0.0-0.9)]。在阴性组的发生率低于 2%的情况下,CARE 规则似乎能够安全排除三分之一胸痛患者和三分之一仅进行单次肌钙蛋白检测的患者发生 MACE 的可能性。